The Readout Loud

Will drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease treatments?

Spyre Therapeutics CEO Cameron Turtle joins the podcast to discuss his company's experimental IBD medications, and whether the drug industry is scraping the barrel in the search for better treatments. We also discuss the latest news in the life sciences, including the ongoing debate between the FDA and UniQure over its Huntington's disease therapy, as well as Moderna's mammoth patent settlement.

On "The Readout LOUD" this week: Adam Feuerstein, solo. His usual co-hosts Allison DeAngelis and Elaine Chen took some time off, so Adam manned the podcast mic himself.

Adam thought, quite understandably, that our cherished listeners wouldn’t want to hear him drone on for 30 minutes, so he thankfully found some help. Jared Holz, health care sector specialist at Mizuho Securities, agreed to be Adam’s podcasting wingman for this week’s show.They ran through a menu of takes on biotech stock performance, M&A, Food and Drug Administration turmoil, election intrigue, and artificial intelligence.

Was Hims' Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what's happening behind-the-scenes with Moderna and the Food and Drug Administration?

We discuss all that on this week's episode of "The Readout LOUD." STAT's Katie Palmer joins Adam, Elaine, and Allison to discuss the Hims GLP-1 pill fallout. The hosts also discuss the latest on Moderna's influenza vaccine application and Compass Pathways' depression psychedelic data.

We’re devoting our entire episode this week to one controversial and impactful topic: the FDA’s decision to block the review of Moderna’s mRNA flu shot.

STAT was the first to report that Vinay Prasad, the agency’s top regulator of vaccines, overruled the head of the FDA’s vaccine office and other staffers in making that decision. Prasad’s unilateral action has renewed concerns about the FDA’s regulatory posture under the Trump administration.

To help us dig deeply into this important story and its ramifications, we bring on STAT reporters Lizzy Lawrence and Matthew Herper. We also chat with Moderna President Stephen Hoge and former FDA official Jesse Goodman.

On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial sickle cell treatment.

It’s our pre-Super Bowl show, which triggered some co-host squabbling. Adam Feuerstein is all Patriots, Elaine Chen is Team Seahawks, while Allison DeAngelis, raised in Seattle but now a Boston denizen, struggles with dual loyalties. Our special guest this week is STAT reporter Jason Mast. And if you get a chance, wish Adam a happy birthday.